EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada

Omolara Fatiregun, Rinku Sutradhar, Sho Podolsky, Andrea Eisen, Lawrence Paszat, Eileen Rakovitch

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2025.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Omolara Fatiregun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Radiology (Clinical Oncology),…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Emigrants and Immigrants, Breast Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johns Hopkins University, Institute for Clinical Evaluative Sciences, Ontario Ministry of Health and Long-Term Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study explored appropriate treatment received for stage 1 and 2 Her2-positive and triple-negative (TN) breast cancer (BC) among immigrants and long-term residents. METHODS: We identified women aged 18- 75 years diagnosed with BC in Ontario from 2012 to 2019. We stratified them into immigrants and long-term residents using the Immigration, Refugee, and Citizenship Canada Permanent Resident database (CIC). We linked to population-wide treatment databases to extract information on breast surgery, chemotherapy, and radiotherapy. We categorized them into 4 mutually exclusive groups based on subtype (Her-2 positive or TNBC) and breast surgery (breast-conserving surgery (BCS) vs. mastectomy). Appropriate treatment included chemotherapy for all (plus Herceptin if Her-2 overexpressing), plus breast radiation therapy if breast-conserving surgery was performed. We could not assess the receipt of endocrine therapy for the hormone receptor-positive subset of Her-2 overexpressors, or indications for postmastectomy radiation therapy. Odds ratios for receiving appropriate treatment were calculated using logistic regression, adjusting for age, resource utilization and area-level residential ethnicity concentration. RESULTS: Crude and univariate analyses showed no differences in the receipt of appropriate treatment. Similarly, adjusted analyses in each of the 4 subgroups showed no difference between immigrants and long-term residents. Among Her2-positive treated by(BCS) group,(Odds Ratio[OR] = 0.82, 95% Confidence Interval[CI] 0.65-1.03, and treated by mastectomy, OR = 0.95 (95% CI, 0.67-1.35). Among TNBC treated by BCS, OR = 0.81 (95% CI, 0.58-1.13), and treated by mastectomy,OR 0.85 (95% CI, 0.49-1.46). CONCLUSION: Immigration status was not associated with the receipt of appropriate treatment amongst early-stage Her2-positive or TNBC breast cancer in Ontario.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsEmigrants and ImmigrantsBreast NeoplasmsHumansFemaleOntarioMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultAgedNeoplasm StagingYoung AdultMastectomyAdolescentMastectomy, Segmental

Stichwörter der Autor:innen

Breast MalignancyCancer ManagementChemotherapyImmigrantsNorth AmericaTargeted therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Radiology (Clinical Oncology), Lagos State University College of Medicine, Lagos, Nigeria.
  • Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
  • Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
  • Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Su…

Förderung

  • Johns Hopkins University
  • Institute for Clinical Evaluative Sciences
  • Ontario Ministry of Health and Long-Term Care
  • Industrial Research and Consultancy Centre

Zitieren

APA

Fatiregun, O., Sutradhar, R., Podolsky, S., Eisen, A., Paszat, L., & Rakovitch, E. (2026). Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.07.013

Vancouver

Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.07.013

BibTeX
@article{Fatiregun2026,
  author = {Fatiregun, Omolara and Sutradhar, Rinku and Podolsky, Sho and Eisen, Andrea and Paszat, Lawrence and Rakovitch, Eileen},
  title = {Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2025.07.013}
}
Kostenlos starten →